HWAM
KALV

Hennion & Walsh Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Hennion & Walsh Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-375,995
Closed -$7.57M – 985
2026
Q1 		$7.57M Buy
375,995
+34,176
+10% +$551K 0.25% 82
2025
Q4 		$5.52M Buy
341,819
+165,236
+94% +$2.19M 0.19% 123
2025
Q3 		$2.15M Buy
176,583
+20,622
+13% +$285K 0.08% 329
2025
Q2 		$1.76M Buy
155,961
+44,855
+40% +$548K 0.07% 339
2025
Q1 		$1.28M Buy
111,106
+36,279
+48% +$370K 0.06% 409
2024
Q4 		$634K Buy
+74,827
New +$775K 0.03% 573

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Hennion & Walsh Asset Management's KALV Position: Q2 2026 in Review

Hennion & Walsh Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 375,995 shares — an estimated $7.57M sold.

Hennion & Walsh Asset Management first reported a position in KALV in Q4 2024 and held it in 6 quarters. The position peaked at $7.57M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Hennion & Walsh Asset Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 375,995 KalVista Pharmaceuticals shares in Q2 2026, an estimated $7.57M.
  • Hennion & Walsh Asset Management first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Hennion & Walsh Asset Management's KalVista Pharmaceuticals position peaked at $7.57M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.